Kyverna Therapeutics Statistics Share Statistics Kyverna Therapeutics has 43.25M
shares outstanding. The number of shares has increased by 0.17%
in one year.
Shares Outstanding 43.25M Shares Change (YoY) 0.17% Shares Change (QoQ) 0.06% Owned by Institutions (%) 51.92% Shares Floating 22.47M Failed to Deliver (FTD) Shares 874 FTD / Avg. Volume 0.24%
Short Selling Information The latest short interest is 1.61M, so 3.72% of the outstanding
shares have been sold short.
Short Interest 1.61M Short % of Shares Out 3.72% Short % of Float 6.47% Short Ratio (days to cover) 5.96
Valuation Ratios The PE ratio is -1.12 and the forward
PE ratio is -1.71.
Kyverna Therapeutics's PEG ratio is
0.
PE Ratio -1.12 Forward PE -1.71 PS Ratio 0 Forward PS 19.1 PB Ratio 0.54 P/FCF Ratio -1.23 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Kyverna Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.61,
with a Debt / Equity ratio of 0.03.
Current Ratio 8.61 Quick Ratio 8.61 Debt / Equity 0.03 Debt / EBITDA -0.07 Debt / FCF -0.07 Interest Coverage -1004.25
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.14M Employee Count 112 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 19.22% in the
last 52 weeks. The beta is 3.75, so Kyverna Therapeutics's
price volatility has been higher than the market average.
Beta 3.75 52-Week Price Change 19.22% 50-Day Moving Average 4.24 200-Day Moving Average 3.24 Relative Strength Index (RSI) 57.23 Average Volume (20 Days) 363,623
Income Statement
Revenue n/a Gross Profit -2.13M Operating Income -142.6M Net Income -127.48M EBITDA -125.2M EBIT -127.33M Earnings Per Share (EPS) -3.33
Full Income Statement Balance Sheet The company has 96.62M in cash and 8.24M in
debt, giving a net cash position of 88.38M.
Cash & Cash Equivalents 96.62M Total Debt 8.24M Net Cash 88.38M Retained Earnings -263.52M Total Assets 226.51M Working Capital 174.54M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -114.25M
and capital expenditures -2.21M, giving a free cash flow of -116.45M.
Operating Cash Flow -114.25M Capital Expenditures -2.21M Free Cash Flow -116.45M FCF Per Share -3.04
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
